C
Christine Sauvage
Publications - 6
Citations - 205
Christine Sauvage is an academic researcher. The author has contributed to research in topics: Randomized controlled trial & Food allergy. The author has an hindex of 5, co-authored 6 publications receiving 128 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial
Jonathan O'b Hourihane,Jonathan O'b Hourihane,Kirsten Beyer,Allyah Abbas,Montserrat Fernandez-Rivas,Paul Turner,Katharina Blumchen,Caroline Nilsson,Maria D Ibáñez,Antoine Deschildre,Antonella Muraro,Vibha Sharma,Michel Erlewyn-Lajeunesse,José Manuel Zubeldia,Frédéric de Blay,Christine Sauvage,Aideen Byrne,John Chapman,Franck Boralevi,Audrey DunnGalvin,Charmaine O'Neill,David Norval,Andrea Vereda,Ben Skeel,Daniel C. Adelman,George Du Toit,George Du Toit +26 more
TL;DR: AR101 oral immunotherapy treatment led to rapid desensitisation to peanut protein, with a predictable safety profile that improved with treatment, and an associated improvement in self-reported and caregiver-reported food allergy-related quality of life.
Journal ArticleDOI
Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow’s milk allergy in toddlers
Nicolas Kalach,Nathalie Kapel,Anne-Judith Waligora-Dupriet,Marie-Christine Castelain,Marie Odile Cousin,Christine Sauvage,Fatimata Ba,Ioannis Nicolis,F. Campeotto,Marie-José Butel,Christophe Dupont +10 more
TL;DR: In this routine diagnosis allergy work-up for CMA in toddlers, the best efficacy was seen for intestinal permeability compared to IgE, IgG, skin prick test and atopy patch test, and fecal EDN in a single spot sample displayed a similar performance.
Journal ArticleDOI
Epicutaneous Immunotherapy (EPIT) Is Effective and Safe to Treat Peanut Allergy: A Multi-National Double-Blind Placebo-Controlled Randomized Phase IIb Trial
Hugh A. Sampson,Wence Agbotounou,Claude Thébault,Ruban Charles,Laurent Martin,William H. Yang,Gordon Sussman,Terri F. Brown-Whitehorn,Kari C. Nadeau,Amarjit Cheema,Stephanie A. Leonard,Jacqueline A. Pongracic,Christine Sauvage,Amal Assa'ad,Frédéric de Blay,J. Andrew Bird,Stephen A. Tilles,Franck Boralevi,Thierry Bourrier,Wayne G. Shreffler,Jacques Hébert,Todd D. Green,Roy Gerth van Wijk,André C. Knulst,Gisèle Kanny,Marek L. Kowalski,Lynda C. Schneider,Pierre Henri Benhamou,Christophe Dupont +28 more
TL;DR: Sampson H.A.H. 3, Sussman G.L.2, Ruban C.C.1, Agbotounou W.K. 2, and Dupont C.2.
Journal ArticleDOI
Peanut Epicutaneous Immunotherapy (EPIT) In Peanut-Allergic Children: 18 Months Treatment In The Arachild Study
Christophe Dupont,Thierry Bourrier,Frédéric de Blay,Lydie Guénard-Bilbault,Christine Sauvage,Marie-Odile Cousin,Gisèle Kanny,Sophie Jarlot,C. Karila +8 more
Journal ArticleDOI
Enhanced Efficacy and Confirmed Safety of a Two-Year Epicutaneous Immunotherapy (EPIT) Treatment of Peanut Allergy with Viaskin® Peanut: The Continuation of the Vipes Phase IIb Randomized Controlled Trial (RCT)
Hugh A. Sampson,Hugh A. Sampson,Wence Agbotounou,Claude Thébault,Charles Ruban,Laurent Martin,Gordon Sussman,Terri F. Brown-Whitehorn,William H. Yang,Kari C. Nadeau,Amarjit Cheema,Stephanie A. Leonard,Christine Sauvage,Amal Assa'ad,Frédéric de Blay,J. Andrew Bird,Stephen A. Tilles,Franck Boralevi,Thierry Bourrier,Pierre-Henri Benhamou,Christophe Dupont +20 more
TL;DR: Endpoint response was based on the proportion of successes, i.e. eliciting dose ≥10-fold above baseline or ≥1,000mg pp, at the 24-month DBPCFC.